USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 5,688 shares of USANA Health Sciences stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $124.27, for a total transaction of $706,847.76. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of USANA Health Sciences stock opened at $123.50 on Friday. The stock has a market capitalization of $3.03 billion, a PE ratio of 30.42 and a beta of 0.64. USANA Health Sciences, Inc. has a 52-week low of $55.50 and a 52-week high of $137.95.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.25. The company had revenue of $301.50 million during the quarter, compared to analysts’ expectations of $278.41 million. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. USANA Health Sciences’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.98 earnings per share. sell-side analysts forecast that USANA Health Sciences, Inc. will post 4.9 EPS for the current year.

Separately, Pivotal Research reaffirmed a “hold” rating and set a $135.00 price objective on shares of USANA Health Sciences in a research report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $135.00.

Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of USANA Health Sciences by 7.3% in the second quarter. Renaissance Technologies LLC now owns 2,105,466 shares of the company’s stock valued at $242,760,000 after acquiring an additional 144,000 shares during the period. BlackRock Inc. boosted its position in shares of USANA Health Sciences by 16.0% in the second quarter. BlackRock Inc. now owns 962,366 shares of the company’s stock valued at $110,961,000 after acquiring an additional 133,076 shares during the period. Acadian Asset Management LLC bought a new stake in shares of USANA Health Sciences in the second quarter valued at about $103,349,000. Dimensional Fund Advisors LP boosted its position in shares of USANA Health Sciences by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 777,313 shares of the company’s stock valued at $66,771,000 after acquiring an additional 14,692 shares during the period. Finally, Millennium Management LLC boosted its position in shares of USANA Health Sciences by 121.4% in the second quarter. Millennium Management LLC now owns 186,974 shares of the company’s stock valued at $21,558,000 after acquiring an additional 102,529 shares during the period. 56.38% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.